Orphazyme A/S logo

ORPHA - Orphazyme A/S Share Price

DKK35.38 -0.9  -2.4%

Last Trade - 12/05/21

Small Cap
Market Cap ÂŁ143.3m
Enterprise Value ÂŁ67.3m
Revenue ÂŁn/a
Position in Universe 811th / 1832
Unlock ORPHA Revenue
Relative Strength (%)
1m -39.9%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -67.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 82.0 260
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Orphazyme A/S revenues was not reported. Net loss increased88% to DKR633.2M. Higher net loss reflects Labor & RelatedExpenses in SGA increase from DKR26M to DKR127.1M (expense), General and administrative expenses increase from DKR23.8Mto DKR119M (expense), Research & Development Expenseincrease of 27% to DKR357.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ORPHA Revenue Unlock ORPHA Revenue

Net Income

ORPHA Net Income Unlock ORPHA Revenue

Normalised EPS

ORPHA Normalised EPS Unlock ORPHA Revenue

PE Ratio Range

ORPHA PE Ratio Range Unlock ORPHA Revenue

Dividend Yield Range

ORPHA Dividend Yield Range Unlock ORPHA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ORPHA EPS Forecasts Unlock ORPHA Revenue
Profile Summary

Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated June 19, 2009
Public Since November 17, 2017
No. of Shareholders: n/a
No. of Employees: 141
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OMX Nordic Exchange - Copenhagen
Shares in Issue 34,952,241
Free Float (0.0%)
Eligible for
View larger map
Address Ole Maaloees Vej 3 Copenhagen N, KOEBENHAVN, 2200, Denmark
Web https://www.orphazyme.com/
Phone +
Contact ()
Auditors Ernst & Young Godkendt Revisionspartnerselskab
ORPHA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ORPHA
Upcoming Events for ORPHA
Frequently Asked Questions for Orphazyme A/S
What is the Orphazyme A/S share price?

As of 12/05/21, shares in Orphazyme A/S are trading at DKK35.38, giving the company a market capitalisation of ÂŁ143.3m. This share price information is delayed by 15 minutes.

How has the Orphazyme A/S share price performed this year?

Shares in Orphazyme A/S are currently trading at DKK35.38 and the price has moved by -65.52% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Orphazyme A/S price has moved by -73.72% over the past year.

What are the analyst and broker recommendations for Orphazyme A/S?

Of the analysts with advisory recommendations for Orphazyme A/S, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Orphazyme A/S is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Orphazyme A/S next release its financial results?

Orphazyme A/S is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Orphazyme A/S dividend yield?

Orphazyme A/S does not currently pay a dividend.

Does Orphazyme A/S pay a dividend?

Orphazyme A/S does not currently pay a dividend.

When does Orphazyme A/S next pay dividends?

Orphazyme A/S does not currently pay a dividend.

How do I buy Orphazyme A/S shares?

To buy shares in Orphazyme A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Orphazyme A/S?

Shares in Orphazyme A/S are currently trading at DKK35.38, giving the company a market capitalisation of ÂŁ143.3m.

Where are Orphazyme A/S shares listed? Where are Orphazyme A/S shares listed?

Here are the trading details for Orphazyme A/S:

Country of listing: Denmark
Exchange: CPH
Ticker Symbol: ORPHA
What kind of share is Orphazyme A/S?

Based on an overall assessment of its quality, value and momentum, Orphazyme A/S is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Orphazyme A/S share price forecast 2021?

Shares in Orphazyme A/S are currently priced at DKK35.38. At that level they are trading at 0.294% discount to the analyst consensus target price of 0.00.

Analysts covering Orphazyme A/S currently have a consensus Earnings Per Share (EPS) forecast of 3.87 for the next financial year.

How can I tell whether the Orphazyme A/S share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Orphazyme A/S. Over the past six months, the relative strength of its shares against the market has been -50.03%. At the current price of DKK35.38, shares in Orphazyme A/S are trading at -51.16% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Orphazyme A/S PE Ratio?

We were not able to find PE ratio data for Orphazyme A/S.

Who are the key directors of Orphazyme A/S?

Orphazyme A/S's management team is headed by:

Martin Bonde - DRC
Thomas Kirkegaard Jensen - CSO
Bo Hansen - VCH
Georges Gemayel - CHM
Anders Fink Vadsholt - CFO
Thomas Blaettler - OTH
Remi Droller - DRC
Martijn Kleijwegt - DRC
Anders Hedegaard - DRC
Catherine Moukheibir - DRC
Christophe Bourdon - CEO
Who are the major shareholders of Orphazyme A/S?

Here are the top five shareholders of Orphazyme A/S based on the size of their shareholding:

Life Sciences Partners Venture Capital
Percentage owned: 7.74% (2.71m shares)
Vaekstfonden Venture Capital
Percentage owned: 5.16% (1.80m shares)
Aescap Venture Venture Capital
Percentage owned: 5.06% (1.77m shares)
Consonance Capital Management LP Hedge Fund
Percentage owned: 3.83% (1.34m shares)
Danske Bank Asset Management Investment Advisor
Percentage owned: 3.46% (1.21m shares)
Similar to ORPHA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.